CDM Projects

This study will determine the percentage of patients with familial hypercholesterolemia achieving the public drug plans' recommended treatment goals with PCSK9 inhibitors and estimate the incidence of major adverse cardiovascular events among patients with familial hypercholesterolemia who are prescribed PCSK9 inhibitors. This project is a collaboration with ADTEC.

We updated our previous study to describe fluoroquinolone utilization trends from 2008 to 2022 and to assess the impact of the risk minimization measures introduced by Health Canada in 2017. Fluoroquinolone use declined in the outpatient setting over the study period, and findings suggest that the regulatory actions could have affected the prescribing of fluoroquinolones.

This study will describe the utilization of long-acting inhaled therapies for COPD in 6 provinces between 2012 and 2024, describing the characteristics of patients at treatment initiation and how treatment evolves over time.

This project is a replication of our previous study. The main objective is to update information on contraception use, pregnancy occurrence, and pregnancy outcomes during isotretinoin therapy.

The objective of this pilot project is to determine the utilization of antidiabetic drugs among pregnant people living in Canada using CNODES' adaptation of the Sentinel Common Data Model.

Opioid use is a potential risk factor for diverticulitis. However, evidence on the association between opioid analgesics and diverticulitis is limited. The overall aim of this study is to evaluate the feasibility of, and subsequently conduct, an observational study evaluating whether short-term and sustained opioid use are associated with elevated risks of diverticulitis in patients indicated for treatment with opioids.